Emerging therapeutic interventions for idiopathic pulmonary fibrosis

Bibliography

• Baumgartner KB, Samet JM, Coultas DB, et al. Occupational and environmental risk factors for idiopathic pulmonary fibrosis: a multicenter case-control study. Collaborating Centers. Am J Epidemiol 2000;152:307-15
   PubMed Web of Science ®Google Scholar
• Collard HR, King TE Jr, Bartelson BB, et al. Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2003;168:538-42
   PubMed Web of Science ®Google Scholar
• Raghu G, Weycker D, Edelsberg J, et al. Incidence and prevalence of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2006;174:810-16
   PubMed Web of Science ®Google Scholar
• Ley B, Collard HR, King TE Jr. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011;183:431-40
   PubMed Web of Science ®Google Scholar
• No authors listed American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med 2000;161:646-64
   PubMed Web of Science ®Google Scholar
• Hunninghake GW, Lynch DA, Galvin JR, et al. Radiologic findings are strongly associated with a pathologic diagnosis of usual interstitial pneumonia. Chest 2003;124:1215-23
   PubMed Web of Science ®Google Scholar
• Flaherty KR, Travis WD, Colby TV, et al. Histopathologic variability in usual and nonspecific interstitial pneumonias. Am J Respir Crit Care Med 2001;164:1722-7
   PubMed Web of Science ®Google Scholar
• Katzenstein AL, Myers JL. Idiopathic pulmonary fibrosis: clinical relevance of pathologic classification. Am J Respir Crit Care Med 1998;157:1301-15
   PubMed Web of Science ®Google Scholar
• Selman M, King TE, Pardo A. Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med 2001;134:136-51
   PubMed Web of Science ®Google Scholar
• Mapel DW, Samet JM, Coultas DB. Corticosteroids and the treatment of idiopathic pulmonary fibrosis: past, present, and future. Chest 1996;110:1058-67
   PubMed Web of Science ®Google Scholar
• Rafii R, Juarez MM, Albertson TE, Chan AL. A review of current and novel therapies for idiopathic pulmonary fibrosis. J Thorac Dis 2013;5:48-73
   PubMed Web of Science ®Google Scholar
• Piguet PF, Collart MA, Grau GE, et al. Tumor necrosis factor/cachectin plays a key role in bleomycin-induced pneumopathy and fibrosis. J Exp Med 1989;170:655-63
   PubMed Web of Science ®Google Scholar
• Raghu G, Brown KK, Costabel U, et al. Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebo-controlled trial. Am J Respir Crit Care Med 2008;178:948-55
   PubMed Web of Science ®Google Scholar
• Ross B, D'Orleans-Juste P, Giaid A. Potential role of endothelin-1 in pulmonary fibrosis: from the bench to the clinic. Am J Respir Cell Mol Biol 2010;42:16-20
   PubMed Web of Science ®Google Scholar
• Saleh D, Furukawa K, Tsao MS, et al. Elevated expression of endothelin-1 and endothelin-converting enzyme-1 in idiopathic pulmonary fibrosis: possible involvement of proinflammatory cytokines. Am J Respir Cell Mol Biol 1997;16:187-93
   PubMed Web of Science ®Google Scholar
• Giaid A, Michel RP, Stewart DJ, et al. Expression of endothelin-1 in lungs of patients with cryptogenic fibrosingalveolitis. Lancet 1993;341:1550-4
   PubMed Web of Science ®Google Scholar
• Schroll S, Arzt M, Sebah D, et al. Improvement of bleomycin-induced pulmonary hypertension and pulmonary fibrosis by the endothelin receptor antagonist Bosentan. Respir Physiol Neurobiol 2010;170:32-6
   PubMed Web of Science ®Google Scholar
• Mutsaers SE, Marshall RP, Goldsack NR, et al. Effect of endothelin receptor antagonists (BQ-485, Ro 47-0203) on collagen deposition during the development of bleomycin-induced pulmonary fibrosis in rats. Pulm Pharmacol Ther 1998;11:221-5
   PubMed Web of Science ®Google Scholar
• King TE Jr, Behr J, Brown KK, et al. BUILD-1: a randomized placebocontrolled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2008;177:75-81
   PubMed Web of Science ®Google Scholar
• Raghu G, Behr J, Brown KK, et al. Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial. Ann Intern Med 2013;158:641-9
   PubMed Web of Science ®Google Scholar
• Gurujeyalakshmi G, Giri SN. Molecular mechanisms of antifibrotic effect of interferon gamma in bleomycin-mouse model of lung fibrosis: downregulation of TGF-beta and procollagen I and III gene expression. Exp Lung Res 1995;21:791-08
   PubMed Web of Science ®Google Scholar
• King TE Jr, Albera C, Bradford WZ, et al. Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial. Lancet 2009;374:222-8
   PubMed Web of Science ®Google Scholar
• Diaz KT, Skaria S, Harris K, et al. Delivery and safety of inhaled interferon-gamma in idiopathic pulmonary fibrosis. J Aerosol Med Pulm Drug Deliv 2012;25:79-87
   PubMed Web of Science ®Google Scholar
• Malouf MA, Hopkins P, Snell G, Glanville AR; Everolimus in IPF Study Investigators. An investigator-driven study of everolimus in surgical lung biopsy confirmed idiopathic pulmonary fibrosis. Respirology 2011;16:776-83
   PubMed Web of Science ®Google Scholar
• Zhang L, Zhu Y, Luo W. The protective effect of colchicine on bleomycin-induced pulmonary fibrosis in rats. Chin Med Sci J 1992;7:58-60
   PubMedGoogle Scholar
• Peters SG, McDougall JC, Douglas WW, et al. Colchicine in the treatment of pulmonary fibrosis. Chest 1993;103:101-4
   PubMed Web of Science ®Google Scholar
• Douglas WW, Ryu JH, Swensen SJ, et al. Colchicine versus prednisone in the treatment of idiopathic pulmonary fibrosis: a randomized prospective study. Members of the Lung Study Group. Am J Respir Crit Care Med 1998;158:220-5
   PubMed Web of Science ®Google Scholar
• Ward WF, Shih-Heollwarth A, Tuttle RD. Collagen accumulation in irradiated rat lung: modification by D-penicillamine. Radiology 1983;146:533-7
   PubMed Web of Science ®Google Scholar
• Chapela R, Zuniga G, Selman M. D-penicillamine in the therapy of fibrotic lung diseases. Int J Clin Pharmacol Ther Toxicol 1986;24:16-17
   PubMedGoogle Scholar
• Günther A, Lübke N, Ermert M, et al. Prevention of bleomycin-induced lung fibrosis by aerosolization of heparin or urokinase in rabbits. Am J Respir Crit Care Med 2003;168:1358-65
   PubMed Web of Science ®Google Scholar
• Kubo H, Nakayama K, Yanai M, et al. Anticoagulant therapy for idiopathic pulmonary fibrosis. Chest 2005;128:1475-82
   PubMed Web of Science ®Google Scholar
• Markart P, Nass R, Ruppert C, et al. Safety and tolerability of inhaled heparin in idiopathic pulmonary fibrosis. J Aerosol Med Pulm Drug Deliv 2010;23:161-72
   PubMed Web of Science ®Google Scholar
• Raghu G, Depaso WJ, Cain K, et al. Azathioprine combined with prednisone in the treatment of idiopathic pulmonary fibrosis: a prospective, double-blind randomized, placebo-controlled clinical trial. Am Rev Respir Dis 1991;144:291-6
   PubMed Web of Science ®Google Scholar
• Zisman DA, Lynch JPIII, Toews GB, et al. Cyclophosphamide in the treatment of idiopathic pulmonary fibrosis: a prospective study in patients who failed to respond to corticosteroids. Chest 2000;117:1619-26
   PubMed Web of Science ®Google Scholar
• Alcorn JF, van der Velden J, Brown AL, et al. c-Jun N-terminal kinase 1 is required for the development of pulmonary fibrosis. Am J Respir Cell Mol Biol 2009;40:422-32
   PubMed Web of Science ®Google Scholar
• Hashimoto S, Gon Y, Takeshita I, et al. Transforming growth factor-beta1 induces phenotypic modulation of human lung fibroblasts to myofibroblast through a c-Jun-NH2-terminal kinase-dependent pathway. Am J Respir Crit Care Med 2001;163:152-7
   PubMed Web of Science ®Google Scholar
• PlantevinKrenitsky V, Nadolny L, Delgado M, et al. Discovery of CC-930,an orally active anti-fibrotic JNK inhibitor. Bioorg Med Chem Lett 2012;22:1433-8
   PubMed Web of Science ®Google Scholar
• Idiopathic Pulmonary Fibrosis Clinical Research Network. Zisman DA, Schwarz M, Anstrom KJ, et al. A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis. N Engl J Med 2010;363:620-8
   PubMed Web of Science ®Google Scholar
• Wilborn J, Bailie M, Coffey M, et al. Constitutive activation of 5-lipoxygenase in the lungs of patients with idiopathic pulmonary fibrosis. J Clin Invest 1996;97:1827-36
   PubMed Web of Science ®Google Scholar
• Peters-Golden M, Bailie M, Marshall T, et al. Protection from pulmonary fibrosis in leukotriene-deficient mice. Am J Respir Crit Care Med 2002;165:229-35
   PubMed Web of Science ®Google Scholar
• Failla M, Genovese T, Mazzon E, et al. Pharmacological inhibition of leukotrienes in an animal model of bleomycin-induced acute lung injury. Respir Res 2006;7:137
   PubMed Web of Science ®Google Scholar
• Leask A, Abraham DJ. The role of connective tissue growth factor, a multifunctional matricellular protein, in fibroblast biology. Biochem Cell Biol 2003;81:355-63
   PubMed Web of Science ®Google Scholar
• Bonniaud P, Martin G, Margetts PJ, et al. Connective tissue growth factor is crucial to inducing a profibrotic environment in “fibrosis-resistant” BALB/c mouse lungs. Am J Respir Cell Mol Biol 2004;31:510-16
   PubMed Web of Science ®Google Scholar
• Allen JT, Knight RA, Bloor CA, Spiteri MA. Enhanced insulin-like growth factor binding protein-related protein 2 (Connective tissue growth factor) expression in patients with idiopathic pulmonary fibrosis and pulmonary sarcoidosis. Am J Respir Cell Mol Biol 1999;6:693-700
   Google Scholar
• Wang Q, Usinger W, Nichols B, et al. Cooperative interaction of CTGF and TGF-β in animal models of fibrotic disease. Fibrogenesis Tissue Repair 2011;4(1):4
   PubMedGoogle Scholar
• Koch HP. Thalidomide and congeners as anti-inflammatory agents. Prog Med Chem 1985;22:165-42
   PubMedGoogle Scholar
• Moreira AL, Sampaio EP, Zmuidzinas A, et al. Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J Exp Med 1993;177:1675-80
   PubMed Web of Science ®Google Scholar
• D'Amato RJ, Loughnan MS, Flynn E, et al. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 1994;91:4082-5
   PubMed Web of Science ®Google Scholar
• Tabata C, Tabata R, Kadokawa Y, et al. Thalidomide prevents bleomycin-induced pulmonary fibrosis in mice. J Immunol 2007;179:708-14
   PubMed Web of Science ®Google Scholar
• Horton MR, Santopietro V, Mathew L, et al. Thalidomide for the treatment of cough in idiopathic pulmonary fibrosis: a randomized trial. Ann Intern Med 2012;157:398-06
   PubMed Web of Science ®Google Scholar
• Oriente A, Fedarko NS, Pacocha SE, et al. Interleukin-13 modulates collagen homeostasis in human skin and keloid fibroblasts. J Pharmacol Exp Ther 2000;292:988-94
   PubMed Web of Science ®Google Scholar
• Saito A, Okazaki H, Sugawara I, et al. Potential action of IL-4 and IL-13 as fibrogenic factors on lung fibroblasts in vitro. Int Arch Allergy Immunol 2003;132:168-76
   PubMed Web of Science ®Google Scholar
• Borowski A, Kuepper M, Horn U, et al. Interleukin-13 acts as an apoptotic effector on lung epithelial cells and induces pro-fibrotic gene expression in lung fibroblasts. Clin Exp Allergy 2008;38:619-28
   PubMed Web of Science ®Google Scholar
• Hancock A, Armstrong L, Gama R, Millar A. Production of interleukin 13 by alveolar macrophages from normal and fibrotic lung. Am J Respir Cell Mol Biol 1998;18:60-5
   PubMed Web of Science ®Google Scholar
• Zhu Z, Homer RJ, Wang Z, et al. Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production. J Clin Invest 1999;103:779-88
   PubMed Web of Science ®Google Scholar
• Kolodsick JE, Toews GB, Jakubzick C, et al. Protection from fluorescein isothiocyanate-induced fibrosis in IL-13-deficient, but not IL-4-deficient, mice results from impaired collagen synthesis by fibroblasts. J Immunol 2004;172:4068-76
   PubMed Web of Science ®Google Scholar
• Belperio JA, Dy M, Burdick MD, et al. Interaction of IL-13 and C10 in the pathogenesis of bleomycin-induced pulmonary fibrosis. Am JRespir Cell Mol Biol 2002;27:419-27
   PubMed Web of Science ®Google Scholar
• Lebtahi R, Moreau S, Marchand-Adam S, et al. Increased uptake of 111In-octreotide in idiopathic pulmonary fibrosis. J Nucl Med 2006;47:1281-7
   PubMed Web of Science ®Google Scholar
• Reynaert H, Rombouts K, Jia Y, et al. Somatostatin at nanomolar concentration reduces collagen I and III synthesis by, but not proliferation of activated rat hepatic stellate cells. Br J Pharmacol 2005;146:77-88
   PubMed Web of Science ®Google Scholar
• Wang J, Zheng H, Hauer-Jensen M. Influence of Short-Term Octreotide Administration on Chronic Tissue Injury, Transforming Growth Factor beta (TGF-beta) Overexpression, and Collagen Accumulation in Irradiated Rat Intestine. J Pharmacol Exp Ther 2001;297:35-42
   PubMed Web of Science ®Google Scholar
• Valatas V, Kolios G, Manousou P, et al. Octreotide regulates CC but not CXC LPS-induced chemokine secretion in rat Kupffer cells. Br J Pharmacol 2004;141:477-87
   PubMed Web of Science ®Google Scholar
• Borie R, Fabre A, Prost F, et al. Activation of somatostatin receptors attenuates pulmonary fibrosis. Thorax 2008;63:251-8
   PubMed Web of Science ®Google Scholar
• Crestani B, Chapron J, Wallaert B, et al. Octreotide treatment of idiopathic pulmonary fibrosis: a proof-of-concept study. Eur Respir J 2012;39:772-5
   PubMed Web of Science ®Google Scholar
• Tager AM, LaCamera P, Shea BS, et al. The Lysophosphatidic acid receptor LPA1 links pulmonary fibrosis to lung injury by mediating fibroblast recruitment and vascular leak. Nat Med 2008;14:45-54
   PubMed Web of Science ®Google Scholar
• Ley K, Zarbock A. From lung injury to fibrosis. Nat Med 2008;14:20-2
   PubMed Web of Science ®Google Scholar
• Kagan HM, Li W. Lysyl oxidase: properties, specificity, and biological roles inside and outside of the cell. J Cell Biochem 2003;88:660-72
   PubMed Web of Science ®Google Scholar
• Boak AM, Roy R, Berk J, et al. Regulation of lysyl oxidase expression in lung fibroblasts by transforming growth factor-β1 and prostaglandin E2. Am J Respir Cell Mol Biol 1994;11:751-5
   PubMed Web of Science ®Google Scholar
• Barry-Hamilton V, Spangler R, Marshall D, et al. Allosteric inhibition of lysyl oxidase-like-2 impedes the development of a pathologic microenvironment. Nat Med 2010;16:1009-17
   PubMed Web of Science ®Google Scholar
• Azuma A. Pirfenidone: antifibrotic agent for idiopathic pulmonary fibrosis. Expert Rev Resp Med 2010;4:301-10
   PubMedGoogle Scholar
• Azuma A, Nukiwa T, Tsuboi E, et al. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2005;171:1040-7
   PubMed Web of Science ®Google Scholar
• Taniguchi H, Ebina M, Kondoh Y, et al. Pirfenidone clinical study group in Japan. Pirfenidone in idiopathic pulmonary fibrosis: a phase III clinical trial in Japan. Eur Respir J 2010;35:821-9
   PubMed Web of Science ®Google Scholar
• Azuma A, Taguchi Y, Ogura T, Pirfenidone Clinical Study Group in Japan. Exploratory analysis of a Phase III trial of pirfenidone identifies a subpopulation of patients with idiopathic pulmonary fibrosis as benefiting from treatment. Respir Res 2011;12:143
   PubMed Web of Science ®Google Scholar
• Atkuri KR, Mantovani JJ, Herzenberg LA. N-Acetylcysteine--a safe antidote for cysteine/glutathione deficiency. Curr Opin Pharmacol 2007;7:355-9
   PubMed Web of Science ®Google Scholar
• Behr J, Maier K, Degenkolb B, et al. Antioxidative and clinical effects of high-dose n-acetylcysteine in fibrosingalveolitis: adjunctive therapy to maintenance immunosuppression. Am J Respir Crit Care Med 1997;156:1897-01
   PubMed Web of Science ®Google Scholar
• Demedts M, Behr J, Buhl R, et al. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 2005;353:2229-42
   PubMed Web of Science ®Google Scholar
• Sime PJ, Xing Z, Graham FL, et al. Adenovector-mediated gene transfer of active transforming growth factor-beta1 induces prolonged severe fibrosis in rat lung. J Clin Invest 1997;100:768-76
   PubMed Web of Science ®Google Scholar
• Kelly M, Kolb M, Bonniaud P, Gauldie J. A re-evaluation of fibrogenic cytokines in lung fibrosis. Curr Pharm Des 2003;9:39-49
   PubMed Web of Science ®Google Scholar
• Bonniaud P, Margetts PJ, Kolb M, et al. Progressive transforming growth factor beta1-induced lung fibrosis is blocked by an orally active ALK5 kinase inhibitor. Am J Respir Crit Care Med 2005;171:889-98
   PubMed Web of Science ®Google Scholar
• Higashiyama H, Yoshimoto D, Kaise T, et al. Inhibition of activin receptor-like kinase 5 attenuates bleomycin-induced pulmonary fibrosis. Exp Mol Pathol 2007;83:39-46
   PubMed Web of Science ®Google Scholar
• Horan GS, Wood S, Ona V, et al. Partial inhibition of integrin alpha(v)beta6 prevents pulmonary fibrosis without exacerbating inflammation. Am J Respir Crit Care Med 2008;177:56-65
   PubMed Web of Science ®Google Scholar
• Amara N, Goven D, Prost F, et al. NOX4/NADPH oxidase expression is increased in pulmonary fibroblasts from patients with idiopathic pulmonary fibrosis and mediates TGFbeta1-induced fibroblast differentiation into myofibroblasts. Thorax 2010;65:733-8
   PubMed Web of Science ®Google Scholar
• Laleu B, Gaggini F, Orchard M, et al. First in class, potent, and orally bioavailable NADPH oxidase isoform 4 (Nox4) inhibitors for the treatment of idiopathic pulmonary fibrosis. J Med Chem 2010;53:7715-30
   PubMed Web of Science ®Google Scholar
• Chilosi M, Poletti V, Zamò A, et al. Aberrant Wnt/beta-catenin pathway activation in idiopathic pulmonary fibrosis. Am J Pathol 2003;162:1495-02
   PubMed Web of Science ®Google Scholar
• Yi ES, Williams ST, Lee H, et al. Keratinocyte growth factor ameliorates radiation- and bleomycin-induced lung injury and mortality. Am J Pathol 1996;149:1963-70
   PubMed Web of Science ®Google Scholar
• Aguilar S, Scotton CJ, McNulty K, et al. Bone marrow stem cells expressing keratinocyte growth factor via an inducible lentivirus protects against bleomycin-induced pulmonary fibrosis. PLoS ONE 2009;4:e8013
   PubMed Web of Science ®Google Scholar
• Chakraborty S, Chopra P, Hak A, et al. Hepatocyte growth factor is an attractive target for the treatment of pulmonary fibrosis. Expert Opin Investig Drugs 2013;22:499-515
   PubMed Web of Science ®Google Scholar
• Marshall RP, Gohlke P, Chambers RC, et al. Angiotensin II and the fibroproliferative response to acute lung injury. Am J Physiol Lung Cell Mol Physiol 2004;286:L156-64
   PubMed Web of Science ®Google Scholar
• Wang R, Ibarra-Sunga O, Verlinski L, et al. Abrogation of bleomycin-induced epithelial apoptosis and lung fibrosis by captopril or by a caspase inhibitor. Am J Physiol Lung Cell Mol Physiol 2000;279:L143-51
   PubMed Web of Science ®Google Scholar
• Otterbein LE, Mantell LL, Choi AM. Carbon monoxide provides protection against hyperoxic lung injury. Am J Physiol 1999;276:L688-94
   PubMed Web of Science ®Google Scholar
• Song R, Kubo M, Morse D, et al. Carbon monoxide induces cytoprotection in rat orthotopic lung transplantation via anti-inflammatory and anti-apoptotic effects. Am J Pathol 2003;163:231-42
   PubMed Web of Science ®Google Scholar
• Chapman JT, Otterbein LE, Elias JA, Choi AM. Carbon monoxide attenuates aeroallergen-induced inflammation in mice. Am J Physiol 2001;281:L209-16
   PubMed Web of Science ®Google Scholar
• Otterbein LE, Bach FH, Alam J, et al. Carbon monoxide has anti-inflammatory effects involving the mitogen-activated protein kinase pathway. Nat Med 2000;6:422-8
   PubMed Web of Science ®Google Scholar
• Zhou Z, Song R, Fattman CL, et al. Carbon monoxide suppresses bleomycin-induced lung fibrosis. Am J Pathol 2005;166:27-37
   PubMed Web of Science ®Google Scholar
• Adamali HI, Maher TM. Current and novel drug therapies for idiopathicpulmonary fibrosis. Drug Des Devel Ther 2012;6:261-72
   PubMed Web of Science ®Google Scholar
• Keane MP, Belperio JA, Burdick MD, et al. ENA-78 is an important angiogenic factor in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2001;164:2239-42
   PubMed Web of Science ®Google Scholar
• Burdick MD, Murray LA, Keane MP, et al. CXCL11 attenuates bleomycininduced pulmonary fibrosis via inhibition of vascular remodeling. Am J Respir Crit Care Med 2005;171:261-8
   PubMed Web of Science ®Google Scholar
• Brewer GJ, Dick R, Ullenbruch MR, et al. Inhibition of key cytokines by tetrathiomolybdate in the bleomycin model of pulmonary fibrosis. J Inorg Biochem 2004;98:2160-7
   PubMed Web of Science ®Google Scholar
• Wang X, Zhu H, Yang X, et al. Vasohibin attenuates bleomycin induced pulmonary fibrosis via inhibition of angiogenesis in mice. Pathology 2010;42:457-62
   PubMed Web of Science ®Google Scholar
• Wan YY, Tian GY, Guo HS, et al. Endostatin, an angiogenesis inhibitor, ameliorates bleomycin-induced pulmonary fibrosis in rats. Respir Res 2013;14:56
   PubMed Web of Science ®Google Scholar
• Pardo A, Selman M. Role of matrix metaloproteases in idiopathic pulmonary fibrosis. Fibrogenesis Tissue Repair 2012;5:S9
   PubMedGoogle Scholar
• Fujita M, Ye Q, Ouchi H, et al. Doxycycline attenuated pulmonary fibrosis induced by bleomycin in mice. Antimicrob Agents Chemother 2006;50:739-43
   PubMed Web of Science ®Google Scholar
• Bhattacharyya P, Nag S, Bardhan S, et al. The role of long-term doxycycline in patients of idiopathic pulmonaryfibrosis: the results of an open prospective trial. Lung India 2009;26:81-5
   PubMedGoogle Scholar
• Mackinnon AC, Gibbons MA, Farnworth SL, et al. Regulation of transforming growth factor-β1-driven lung fibrosis by galectin-3. Am J Respir Crit Care Med 2012;185:537-46
   PubMed Web of Science ®Google Scholar
• Allen JT, Spiteri MA. Growth factors in idiopathic pulmonary fibrosis: relative roles. Respir Res 2002;3:13
   PubMed Web of Science ®Google Scholar
• Hilberg F, Roth GJ, Krssak M, et al. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res 2008;68:4774-82
   PubMed Web of Science ®Google Scholar
• Richeldi L, Costabel U, Selman M, et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med 2011;365:1079-87
   PubMed Web of Science ®Google Scholar
• Antoniades HN, Bravo MA, Avila RE, et al. Platelet-derived growth factor in idiopathic pulmonary fibrosis. J Clin Invest 1990;86:1055-64
   PubMed Web of Science ®Google Scholar
• Daniels CE, Wilkes MC, Edens M, et al. Imatinibmesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis. J Clin Invest 2004;114:1308-16
   PubMed Web of Science ®Google Scholar
• Daniels CE, Lasky JA, Limper AH, et al. Imatinib-IPF Study Investigators.Imatinib treatment for idiopathic pulmonary fibrosis: randomized placebo-controlled trial results. Am J Respir Crit Care Med 2010;181:604-10
   PubMed Web of Science ®Google Scholar
• Vittal R, Fisher A, Gu H, et al. Peptide-mediated inhibition of mitogen-activated proteinkinase-activated protein kinase-2 ameliorates bleomycin-induced pulmonary fibrosis. Am J Respir Cell Mol Biol 2013;49:47-57
   PubMed Web of Science ®Google Scholar
• Conte E, Gili E, Fruciano M, et al. PI3K p110gamma overexpression in idiopathic pulmonary fibrosis lung tissue and fibroblast cells: in vitro effects of its inhibition. Lab Invest 2013;93:566-76
   PubMed Web of Science ®Google Scholar
• Wei X, Han J, Chen ZZ, et al. A phosphoinositide 3-kinase-gamma inhibitor, AS605240 prevents bleomycin-induced pulmonary fibrosis in rats. Biochem Biophys Res Commun 2010;397:311-17
   PubMed Web of Science ®Google Scholar
• Russo RC, Garcia CC, Barcelos LS, et al. Phosphoinositide 3-kinase γ plays a critical role in bleomycin-induced pulmonary inflammation and fibrosis in mice. J Leukoc Biol 2011;89:269-82
   PubMed Web of Science ®Google Scholar
• Scotton CJ, Chambers RC. Bleomycin revisited: towards a more representative model of IPF? Am J Physiol Lung Cell Mol Physiol 2010;299:L439-41
   PubMed Web of Science ®Google Scholar